Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K and 20 more

Show all authors

Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ

The New England journal of medicine6 Apr 2024Cited by 622 (Europe PMC)

PMID38587233DOI10.1056/nejmoa2313917PepBankPUB-38587233

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide improved the KCCQ clinical summary score more than placebo.
In plain wordsIn adults with obesity, type 2 diabetes and heart failure, semaglutide improved symptom scores more than placebo.
Peptide
Semaglutide
Outcome
IncreaseKCCQ-CSS change at 52 weeks
Study
n = 616
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
KCCQ-CSS change
13.7 points
semaglutide
KCCQ-CSS change
6.4 points
placebo
estimated difference
7.3 points
semaglutide vs placebo
Source sentences
Summary
The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3858723301
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide reduced body weight more than placebo.
In plain wordsIn adults with obesity, type 2 diabetes and heart failure, semaglutide led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight percentage change
Study
n = 616
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
body weight change
−9.8%
semaglutide
body weight change
−3.4%
placebo
estimated difference
−6.4 percentage points
semaglutide vs placebo
Source sentences
Summary
and the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3858723302
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide increased 6-minute walk distance more than placebo.
In plain wordsIn adults with obesity, type 2 diabetes and heart failure, semaglutide increased walking distance more than placebo.
Peptide
Semaglutide
Outcome
Increase6-minute walk distance change
Study
n = 616
Comparator
Placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
6-minute walk distance difference
14.3 m
semaglutide vs placebo
Source sentences
Summary
estimated between-group difference in change in 6-minute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P = 0.008]
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3858723303
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, the hierarchical composite end point favored semaglutide over placebo.
In plain wordsIn adults with obesity, type 2 diabetes and heart failure, a combined measure of outcomes favored semaglutide over placebo.
Peptide
Semaglutide
Outcome
IncreaseHierarchical composite end point
Study
n = 616
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
win ratio
1.58 ratio
semaglutide vs placebo
Source sentences
Summary
win ratio for hierarchical composite end point, 1.58 [95% CI, 1.29 to 1.94; P<0.001]
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3858723304
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide lowered C-reactive protein more than placebo.
In plain wordsIn adults with obesity, type 2 diabetes and heart failure, semaglutide lowered an inflammation marker more than placebo.
Peptide
Semaglutide
Outcome
DecreaseC-reactive protein change
Study
n = 616
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
CRP treatment ratio
0.67 ratio
semaglutide vs placebo
Source sentences
Summary
estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3858723305
06HumanRandomized controlled trialSafety outcome
In adults with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, fewer participants had serious adverse events with semaglutide than with placebo.
In plain wordsIn adults with obesity, type 2 diabetes and heart failure, fewer people had serious adverse events with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseSerious adverse events
Study
n = 616
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
participants with serious adverse events
55 participants
semaglutide
participants with serious adverse events
88 participants
placebo
Source sentences
Summary
Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3858723306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT04916470

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Novo Nordisk A/Sn = 61715 Jun 2021 to 11 Oct 2023

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.